Delivery Order SPE2DB22D1017-SPE2DB25FG9CH
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,021.20 on August 13, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL. This is a firm fixed-price, non-set-aside competitive award with a performance location in Conshohocken, Pennsylvania, and an ultimate completion date of August 14, 2025. The delivery order represents a single transaction under AmerisourceBergen's larger federal contract vehicle with the Defense Logistics Agency. This delivery...
- The Defense Logistics Agency awarded a $2,416.05 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 29, 2025. This non-competitive delivery order was placed against AmerisourceBergen's broader pharmaceutical supply contract vehicle and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA(CF) Pen 40 MG/0.4 MLS on June 17, 2025, with a ceiling value of $3,095.26. This is a firm fixed-price delivery order with no set-aside designation, reflecting AmerisourceBergen's capability to compete in open federal procurement. The drug will be delivered to the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of June 18, 2025. This award represents a routine...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a specialty pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, valued at $11,500.66, is scheduled for completion by August 14, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL with a ceiling value of $1,185.69. This is a firm fixed price delivery order under a non-set-aside competitive procurement. The contract is set to be completed by August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $43,110.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with final delivery required by July 15, 2025. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery at its corporate office location. This delivery order is issued...
- The Defense Logistics Agency awarded a $9,183.92 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 29, 2025, with a completion date of July 30, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a single delivery under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The product will be delivered to AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $19,774.30 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a ceiling value of $999,999,999.00 through December 2026. The performance location is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,387.94 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on October 23, 2025, with an ultimate completion date of October 24, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. HUMIRA is a widely-used biologic medication for treating autoimmune conditions, and this order represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL with a ceiling value of $1,142.05. This is a firm fixed-price delivery order with no set-aside designation, executed under competitive procedures. The contract is scheduled for completion by September 17, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a biologic...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG9CHDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 6, 2025, with a ceiling value of $3,021.20. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 7, 2025. This delivery order represents a single transaction under AmerisourceBergen's comprehensive pharmaceutical supply contract with the Defense Logistics Agency, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen supplies a wide range of medications and medical supplies to support military and veteran healthcare systems. HUMIRA, a brand-name biologic medication, is one of many therapeutic products the company provides through its DLA framework, which supports Defense Health Agency operations and other government healthcare systems globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 8/6/25 |